ArticleCancer immunology research2020
Tumor Antigen Heterogeneity: The "Elephant in the Room" of Adoptive T-cell Therapy for Solid Tumors.
Article in Cancer immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives.iScience · 2026Review
- Optimizing CAR T cell therapy for solid tumours: a clinical perspective.Nature reviews. Clinical oncology · 2025Review
- Article
- Developing CAR T-Cell Therapies for Pediatric Solid Tumors.Paediatric drugs · 2025Review
- Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.Cancer immunology, immunotherapy : CII · 2024Article
- CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.Nature reviews. Clinical oncology · 2024Review
- Imaging CAR T-cell kinetics in solid tumors: Translational implications.Molecular therapy oncolytics · 2021Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major hurdle to the efficacy of adoptive cell therapy and chimeric antigen receptors T-cell therapy is the choice of antigen(s) to target. An article in this issue addresses this by capitalizing on the synergistic effect of pathogen-based immunotherapy and adoptive cell therapy that results in epitope/antigen spreading and enhancement of the endogenous T-cell response against antigens not originally targeted.
Indexed as
Identifiers
31909728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.